Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,199 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

40,199 Papers indexed
1,440 Papers AI scored
40,199 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40199 results
C
AI -
Standard 55.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 55.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

C
AI -
Standard 55.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 55.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 20.0; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

C
AI -
Standard 55.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 55.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

C
Pediatric Cancer Predisposition and Surveillance Update: Summary Perspective and Future Directions.
PMID 40327330 Published: 2025-07-01 Ingested: 2026-08-02 12:04 AM Clinical cancer research : an official journal of the American Association for Cancer Research
AI -
Standard 55.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 55.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

C
Increased expression of proinflammatory cytokines in the cerebrospinal fluid of patients with a history of electrical status epilepticus in sleep.
PMID 40323354 Published: 2025-05-05 Ingested: 2026-08-02 12:04 AM Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
AI -
Standard 55.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 55.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

C
Melamine derivatives in indoor dust from China: Temporal trends and human exposure before and during COVID-19 pandemic.
PMID 40319858 Published: 2025-04-29 Ingested: 2026-08-02 12:04 AM Journal of hazardous materials
AI -
Standard 55.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 55.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

C
AI -
Standard 55.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 55.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

C
Worth the Effort: Lessons for Discovery and Care From an Unusual Case of Gorlin Syndrome.
PMID 40317671 Published: 2025-05-03 Ingested: 2026-08-02 12:04 AM American journal of medical genetics. Part A
AI -
Standard 55.0
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 55.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

Previous
Page 2622 of 3350
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic